Close Menu

More articles about Research & Discovery

Subscribers: click headline for more

Subscribers: click headline for more

Subscribers: click headline for more

For most well-known proteomics companies, partnering with pharma is a little like trying to hold on to the back of a bus while bicycling: the longer you can hang on while a protein target works its way through the pipeline, the better chance for seeing royalties down the road. .Subscribers: click headline for more

Looking ahead to 2002, HUPO President Sam Hanash told ProteoMonitor he expects the coming year to be critical both for proteomics companies and the organization he leads, as the two try to prove they can live up to their potential. .Subscribers: click headline for more

.Subscribers: click headline for more

For the first time in their 14 month-old research partnership, Novartis has accepted six of GeneProt s synthetic proteins for further drug development, the two companies said December 20. Subscribers: click headline for more

Subscribers: click headline for more

When Applied Biosystems introduced a commercial version of the ICAT reagent technology last March, proteomics researchers had high hopes that at long last a method for performing high-throughput differential protein analysis had emerged to provide an alternative to the drudgery of 2D gel electrophoresis. Subscribers: click headline for more

Pharmaceutical companies have long relied on x-ray crystallography to help refine their candidate small molecule drugs, but a deal signed last week between Structural Genomix (SGX) of San Diego and Heidelberg-based Graffinity may be the first to combine the new breed of high-throughput protein crystallography with array-based approaches to finding drug leads. Subscribers: click headline for more

IBM continued its penetration of the proteomics market last week, as protein database provider GeneFormatics chose the company to provide computing equipment and support. Subscribers: click headline for more

Two Munich startups, Nanotype and Xerion Pharmaceuticals, have joined forces to develop a protein chip for studying neural stem cell behavior and differentiation, Nanotype said Dec. 13. Subscribers: click headline for more

Subscribers: click headline for more

In previous conference presentations, Scott Patterson, Celera Genomics vice president for proteomics, has indicated that the company is pursuing a focused approach to discovering potential drug targets and markers Subscribers: click headline for more

Oxford GlycoSciences has filed patent applications on 4,000 disease-associated proteins, protein isoforms, and their genes, accomplishing a goal the company set for itself in March 2000, the Abingdon, UK-based company said Dec. 7 Subscribers: click headline for more

Providing further evidence that scientists from diverse disciplines are seeking to apply proteomics techniques to their research, a symposium earlier this month sponsored by the NIH s National Center for Toxicogenomics featured prominent players from the field of proteomics, including Denis Hochstrasser, a founder of GeneProt, and Emanuel Petricoin, a co-director of the joint NCI-FDA clinical proteomics program Subscribers: click headline for more

Subscribers: click headline for more

MDS Proteomics plans to go through with an initial public offering next year to acquire additional funding, the company s new CFO said last week Subscribers: click headline for more

Subscribers: click headline for more

Pages

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.